



French
Healthcare
法国健康产业联盟

Introduction Book

V1.0

An introduction from the co-chairmen



Anne BRUANT BISSON



Olivier DESSAJAN



Antoine OUSTRIN

Since its founding in 2013, The French Healthcare Alliance in China has sought to develop the best healthcare solutions for the Chinese society and the strongest collaboration in this field between France & China. As a French organization, our objectives are to promote French Healthcare excellence with the introduction of innovative companies, to organize meetings between experts and to create joint business synergies.

The French Healthcare Alliance is the union of more than 150 companies & institutions from various fields such as chronic diseases, infectious diseases, rare diseases, ageing industry and digital health. Our members already have impressive track records and are developing innovative solutions in China, for China.

With the support of the French Embassy and Business France, our organization aims to enhance the relationship and understanding between French and Chinese stakeholders by organizing:

- 1) Medical conferences, such as the Sino-French medical seminars on diabetes in Beijing in 2019 and the French Medical Day in Shenzhen in 2020 with focus on rare diseases, infectious diseases and elderly care. Oncology will be the focus of this year's edition, in Shanghai this November.
- 2) French Pavilions at professional fairs such as CMEF for medical devices and China Aid on the silver economy.
- 3) Webinars every month since 2020 on several topics such as vaccines, hypertension, infectious diseases, silver economy, E-health, etc
- 4) Delegations in major Chinese cities to expand the relationship between local companies and French ones and create business opportunities.

Platform of information and discussions between industry specialists. We hope that this brochure will provide an interesting insight into French Healthcare excellence and encourage you to come and join us.

Table of content

An introduction from the co-chairmen	2
Who are we?	4
Our goals: to support the development of French companies in China, for China	4
Our members	5
Our Events & Activities	6
FRANCE: HEALTHCARE EXCELLENCE	7
FRANCE: A WORLD INNOVATIVE LEADER	8
AGING WORKING GROUP	9
China & France: caring for the elderly together	9
“Caring for a better life”.	10
“The best advanced and innovative solutions in China for a better life”	11
“Caring for the elderly together”	12
The French silver economy in China	12
Case Studies	12
CHRONIC DISEASES WORKING GROUP	15
China & France: Working together	15
French added value	16
“Cardiovascular diseases management is a top priority”	17
“The right value at each step of the cardiovascular patient journey”	18
Case study	19
“Beside the cardiovascular patients with optimal solutions”	21
INFECTIOUS DISEASES WORKING GROUP	22
Innovating to improve public health capabilities.	25
Case Study: Biomerieux Collaborations with Chinese medical institutions	26
Case Study: Sanofi’s commitment to public health in China and to vaccine innovation	27
E-HEALTH WORKING GROUP	28
French added value	28

Who are we?

Launched in 2013, we are an alliance of over 150 French healthcare players working in China. Together we represent the diversity of French healthcare expertise and contributions.



Our members are pharmaceuticals / biotech, medical technology and digital health companies, public private hospitals, nursing home operators, architects, collective services and training providers, research institutes, etc.

Our goals: to support the development of French companies in China, for China



Our members

Our Steering Committee

STEERING COMMITTEE



FRENCH EMBASSY



Our members: A complete range of healthcare expertise

150+ MEMBERS



Our Events & Activities


Regular online & offline events



FHA plenary in Shanghai



Webinar infectious diseases




Webinar patients meet doctors



FHA plenary Beijing

Fairs & delegations



CIIE French booth



Sino French medical day



Tencent Shenzhen delegation



JD health Beijing delegation

Targeted actions & working groups



E-health working group



Purchase support during covid-19



Sourcing support group



Elderly working group

FRANCE: HEALTHCARE EXCELLENCE

13&9

13 Nobel Prizes for medicine &
9 Nobel Prizes for chemistry

4/25

4 public research institutions listed in the top 25 in the world
National Centre for Scientific Research (CNRS), National
Institute of Health and Medical Research (Inserm), French
Alternative Energies and Atomic Energy Commission (CEA),
Pasteur Institute (Microbiology/ infectious disease)

7

7 French pharmaceutical
companies among the world
leaders: BioMérieux, Guerbet,
Ipsen, LFB, Sanofi, Servier, Théa

1400

1,400 companies developing,
creating, manufacturing or
distributing healthcare products

9.8%

9.8% of French
pharmaceutical companies'
revenues spent in R&D

1st

First country in Europe to
establish a national plan on rare
diseases (2003)

2nd

Rated second in European
countries for advanced therapy
drugs (cell/gene therapy) with 84
products in development in 2019

1st

One National Health Data
Platform, enhancing French
strategy for joint e-health
innovation between private
and public health providers
and patients

FRANCE: A WORLD INNOVATIVE LEADER

1st

First within the Euronext: 90 biotech and medtech companies listed, 69 are French companies

4

4 Number one country in Europe for biotechnologies patent filing and fifth in the world for medical devices patent filing.

12%

12 % of industrial clinical trials conducted globally in 2018

127

127 world firsts since 1958 from French Hospitals: First carotid artery stent in 1990; the first use of an autonomous artificial

2nd

Second country in the world in terms of number of clinical trials in the fields of oncology and gene therapy

2nd

Second most innovative country with 10163 patents pending in 2019

AGING WORKING GROUP

In China, the French Healthcare Alliance ageing group brings a unique accumulation of know-how and the best international solutions which have already been tailored to the local specificities and already proven their efficiency in China.

China & France: caring for the elderly together



At the “French Healthcare Alliance Ageing Group” in China, we understand the need to develop the best innovative solutions in this fast-growing market: “ageing in China - silver industry”.

“Caring for a better life”



China will soon have the world’s largest ageing population, generating an unprecedented demand for elderly-care services (By 2050, 1 in 3 people will be over 60). Recognizing this demographic revolution and the resulting healthcare challenges, the Chinese authorities & the all society have initiated significant reforms to provide a better framework for healthy ageing, including the development of the “silver industry” targeting both homecare & residential care.

French players have taken the lead in developing innovative high-end solutions for dependent people including scientific studies aiming at promoting elderly’s people well-being, health and safety. Today, French companies are the major leaders of the industry in Europe and at the forefront worldwide for quality solutions.

In China, the French Healthcare Alliance ageing group brings a unique accumulation of know-how and the best international solutions which have already been tailored to the local specificities and already proven their efficiency in China. This global service includes:

- **Nursing home management to the senior apartment solutions:** The most advanced residential care providers worldwide.
- **Architecture & interior design:** innovation, adaptation & integration of the needs of residents & their family.
- **Staff training:** developing the competences of all the staff for a better quality of service & a new model of management.
- **Hospitality management:** customized solutions for creating the best environment for a better senior life.
- **Smart elderly care system** for consistent and efficient care quality & healthcare supervision.
- **Rehabilitation devices and support solutions:** restoring functional ability and quality of life for all the elderly people.
- **Insurance:** financing long-term care & providing the right solution for all the families.

“The best advanced and innovative solutions in China for a better life”

In order to be successful in this emerging market, it is vital to enhance your quality & management system by using international competences which already have a scientifically proven benefit. However, a full range of expertise is essential for delivering the best solutions for the Chinese society. We also believe that is an important social mission to deliver the most innovative and efficient solutions for Chinese senior citizens.

We understand that it is a new service and industry in China, that is why we are here to assure you that based on our international & Chinese experience we can help you to deliver the best solutions for Chinese senior citizens now.



How to establish a sustainable partnership with the French healthcare alliance ageing group and its members?

- 1. Read this brochure and meet our members
- 2. Experience their added value and solutions already implemented in China
- 3. Define the right solution for you
- 4. Establish the right business model & partnership

We can help you to enter this market and become an international solution provider with the best solutions developed and ready to expand your success in a promising Chinese market.

Enjoy your lecture and let's organize a meeting or visit now!

“Caring for the elderly together”



The French silver economy in China

More than 10 high end projects in China: innovative nursing homes and elderly projects operated by French operators including 4 already under operation since 2018.

More than 400 projects integrating French silver economy solutions in more than 30 different Cities.

20+ high end French companies (Architects, security solutions, service providers, training institutions...) which already demonstrated their added value in China.

All the competences and solutions required for entering this large and diverse market with more than 20 French companies successfully established in Europe and already settled in China

Case Studies

Excellence and International standards integrated in Chinese medical nursing home & senior apartment: ORPEA, COLISEE with more than 4 years of operation in China & many awards received as the best operators. They demonstrated the added value of their solutions and established a new model in China for a better life & health for Chinese senior citizens.



Huge experience in China: LEGRAND has been providing Smart Systems since 2015 for better healthcare & security in senior care solutions. Already installed in more than 300 projects.



申养中心·望年荟
上海



伯仁堂龙吴路养老院
上海



游福老年公寓
上海



明诗常青藤·颐养中心
南京



泰康燕园
北京



寸草春晖养老院
北京



首开益头养老院
北京



皇姑万科怡园
沈阳



招商高利泽康颐养中心
广州



新海颐养苑
广州



招商观颐之家
深圳



远洋精壹茂
武汉





Innovation & pioneering solutions: Hinounou InsurTech solution already launched and dedicated to the 200 million seniors in China – providing the only fully integrated eHealth solution for senior citizens at home that combine health monitoring, telemedicine, and insurance protection with platform management for senior care professionals. It is already used by 10,000 families in China in more than 60 cities.

Implementation of new techniques, competences and solutions for a better service: High level & innovative training institutions like ISRP. As the creator of the psychomotor therapy and founder of the School, ISRP has been delivering the know-how to over 6000 Chinese medical and paramedical professionals in the health care field through its continuing and original education for over 6 years in China.



CHRONIC DISEASES WORKING GROUP

In China, the French Healthcare Alliance Chronic Diseases group is fully committed to serve the needs of patients with chronic diseases. According to WHO, in 2000: "France provides the best overall healthcare in the world"

**Together, for an Optimal management of
chronic diseases patients**



CHRONIC DISEASES WORKING GROUP

The French health care system is fully committed to serve the needs of patients with chronic diseases. According to WHO, in 2000: “France provides the best overall Healthcare in the world”
How does the French Healthcare system add value for the management of chronic diseases?

■ 1- The Universal access to Healthcare

France with its model of Universal access to Healthcare based on solidarity, is the number one OECD country for access to Healthcare, with the lowest remaining balance amount payable by patients. In particular, there is 100% cover for patients diagnosed with chronic diseases.

■ 2- The Excellence

France was the first country in Europe to establish a national plan on rare diseases in 2003 and is the second rated European country in advanced therapy drugs. Furthermore, the French pharmaceutical industry has a long-standing presence in China and France is the fifth largest pharmaceutical market worldwide.

■ 3-The patient journey management

Since the beginning, the management of chronic disease patients has been one of our strengths. At each step, France can provide a unique quality of products: pharmaceuticals, bio-innovation, medical devices, digital and supportive care.

Cardiovascular diseases are highly prevalent in China and pose significant Health and Economic burden; even though their management has improved in recent years, China still faces challenges.

Indeed, hypertension, diabetes and dyslipidemia are known to be major cardiovascular risk factors of severe and expensive complications generating disability or death, such as strokes, myocardial infarction or heart failure.

With the Healthy CHINA 2030 plan, China’s leaders ensured Health became an explicit national priority. Therefore, a key component of this program is the prevention of cardiovascular diseases and the promotion of healthy lifestyles.



“Cardiovascular diseases management is a top priority”

The cardiovascular patient should be considered during his whole journey: awareness, diagnosis, treatment, adherence, and control. In this patient journey, the expertise of the “French Healthcare Alliance Chronic Diseases Group” is strongly established and proposes complete solutions (Therapeutic, medical device, technological, digital).



The **French Healthcare Alliance** is a group of 135 French healthcare companies, which promotes Sino-French collaboration. This active group develops relationships, scientific added value, financial and commercial partnerships between French healthcare companies and local stakeholders (Chinese authorities at the national and local level, investors, hospitals, research institutes).



Hypertension Awareness campaign 2021 #BecauseI sayso, piloted by Servier in collaboration with ISH (International Society of Hypertension), CHL (Chinese Hypertension League) and Shanghai Institute of Hypertension.

Within our **chronic diseases group**, we are strongly committed to propose the right value at each step of the cardiovascular patient journey.

Such as **pharmaceutical solutions**, involving worldwide leaders in the cardiologic field, concerning the treatment of hypertension, diabetes, dyslipidemia or chronic heart failure. Our alliance can also propose **digital and innovative AI solutions**, such as the AI Preventive Platform that collects and analyzes self-generated biobehavioral data to offer a virtual digital twin representation, in order to help chronic diseases patients to live longer and healthier at home.

“The right value at each step of the cardiovascular patient journey”



With these innovative solutions, we can contribute to strengthen the prevention, the diagnosis and the treatment of Hypertension and Diabetes, in order to avoid severe complications, expensive hospitalizations and disabilities, and also to provide solutions for severe cardiac diseases such as chronic heart failure. China is facing a real challenge with a huge population, a large territory, and different levels of access to healthcare between cities and rural areas.

We strongly believe it is an important social mission to be pro-active and to provide high-level care solutions from the start, for the benefit of the whole Chinese population.

We know that the management of cardiovascular risk factors is one of the top public healthcare priorities, worldwide, but especially in China, with the Healthy China 2030 plan.

Our French healthcare partners can contribute to ensure the right solution to optimize the Chinese cardiovascular patient path.

Case Studies

Pharmaceutical area:

Servier is an international leader in the pharmaceutical field and especially in cardiovascular and metabolic areas.



In China, **Servier** is one of the leaders in cardiology, hypertension, diabetes and in community hospitals. Servier China is the first subsidiary of **Servier** group, based in Beijing with 6 regional offices covering 29 Chinese provinces, with its own Production site (Tianjin), clinical development (Beijing) and BioInnovation.

In 2018, Servier established its **BioInnovation** in China and in the United States, focusing on preclinical and early clinical innovation. By researching and collaborating with the world's leading life sciences and biomedical research centers, we co-create and drive innovation in therapeutic options. With a focus on R&D and early clinical development, Servier has partnerships throughout the product lifecycle management process.



Servier BioInnovation Seminar, Shanghai Nov 2020

In January 2020, Servier China won the “**Health China (2019) Health Welfare Project of the Year-Outstanding Organization Award**”, for Because I say So, the global high Blood Pressure awareness campaign.



Case Studies


In 2020, **Servier China** signed new partnerships to expand channels for supplying products to market for the benefits of patients, with:

- **National and local distributors:** one with **SHAPHAR** (Shanghai pharmaceutical and co.) and one with **SINOPHARM** (during the 3rd China International Import Expo).



Partnership with SINOPHARM

- **E-commerce:** with **Alibaba Health** (during the 3rd China International Import Expo) and **JingDong (JD)**.



Partnership with Alibaba Health

- **Top pharmacy chains:** with Yixintang (Yixintang Pharmaceutical Group Co.) and Cowell Health.

The digital branch of Servier **We Health** is also committed to providing efficient e-solutions through close collaboration with advanced start-ups.



Servier China has been offering high quality drugs (hypertension, diabetes, chronic heart failure and chronic venous diseases) and innovative services from more than 40 years to fully serve patient needs.

1979 施维雅成为最早进入中国的跨国公司之一
Servier became one of the first multinational pharmaceutical companies to enter China.

1980 施维雅与中华医学会共同创办中法医学交流项目，得到时任中共中央副主席邓小平的支持，由此拉开了中法医学交流的历史大幕
Supported by Deng Xiaoping, Vice Chairman of the CPC Central Committee, Servier sponsored the Sino-French Medical Exchange Project with the Chinese Medical Association. It started a long history of Sino-French medical exchanges.

1987 施维雅与天津华津合作，共同引进以美隆®，开创中国合作生产药品的先例
Cooperating with Tianjin Huajin, Servier introduced Omeprazol® to China, creating a precedent of cooperative production of drugs in China.

1998 施维雅中国总部迁至北京，对中国专业医药人员及患者承诺再升级
Servier China moved its headquarter to Beijing, reaffirming our commitment to Chinese medical professionals and patients.

2000 施维雅(天津)制药有限公司于天津经济技术开发区注册成立，和天津华津制药有限公司共同开启了协同发展的新篇章
Servier (Tianjin) Pharmaceutical was established in the Tianjin Economic Technological Development Area (TEDA). Together with Tianjin Huajin Pharmaceutical Company, Servier China opened a new chapter of coordinated development.

2001 施维雅北京医药研发中心正式成立，成为施维雅全球第12个研发中心
Servier Beijing Pharmaceutical R&D Co., Ltd. was established. It's the 12th R&D Center of Servier worldwide.

2002 施维雅天津工厂正式投产，实现多种优势药物的本地化生产，满足中国大陆、亚太多个国家和地区的临床需求
Servier's Tianjin plant began production, producing high-quality drugs to meet demand in mainland China and other countries in the Asia Pacific region.

2015 施维雅中国成为集团首 全球排名第一的分公司，目前，施维雅中国业务覆盖29个省市地区，成为集团最大的专业团队
Servier China's turnover ranked first in the Servier Group. Currently with its business covering 29 provinces and municipalities, and with the largest professional team in the Servier Group.

2018 施维雅天津工厂扩建完工，新的制车间建成，生产能力翻一番，成为生产更多创新药的研发基地
Servier expanded its Tianjin plant. The production capacity will double when the new factory is completed, enabling the production of more innovative drugs in the future.

2019 施维雅中国成立40周年
40th Anniversary of Servier China

What is our plan:

- Meet all our French stakeholders involved in the cardiovascular area
- They can share their experience worldwide and then in China
- Define the key points and the different steps for the best strategy
- Create a business model

Subsequently, we can organize virtual or face to face regular meetings, with all the designed partners or specific ones. We hope that this collaboration will be successful with many optimal care solutions and simultaneous economic benefits.

**“Beside the cardiovascular patients
with optimal solutions”**



INFECTIOUS DISEASES WORKING GROUP

A long history of partnership with China to strengthen epidemic preparedness and control ...

The French Healthcare Alliance infectious diseases working group plays a **key role in epidemic preparedness and control in China.**

Leveraging centuries of French medical excellence and the scientific legacy of Dr. Louis Pasteur, we have been contributing to reinforce **China's public health capabilities for decades**, through a holistic approach to prevent and combat infectious diseases in China.

...with world leaders in diagnostics and vaccines.

Our working group members, **BioMérieux** and **Sanofi**, are world class leaders headquartered in France in the respective fields of in vitro diagnostics and vaccines. They have been growing in and with China for over 30 years, **to improve the health of the Chinese population.**




We believe in a world in which no one suffers or dies from communicable diseases.



We are committed to becoming trusted public health partners of the Chinese government and to contribute to improving China's **public health capabilities, epidemic preparedness, and control**. Achieving these goals requires cutting-edge and multiple solutions to improve the prevention, the diagnosis and the treatment of infectious diseases with high efficacy.

The problem is that infectious disease outbreaks are ever-increasing, exposing populations to unprecedented public health risks. We believe epidemic risks should be further mitigated to avoid dramatic death tolls, as well as significant social and economic impact on people's daily life. The current pandemic has reinforced our ambition to fulfil these unmet medical needs together with China.



A holistic offering from prevention to control...



In China, our working group provides a comprehensive offering ranging from prevention to control, covering most urban and remote rural areas in China.

We understand the need to better prevent and control epidemics with high quality, safe vaccines and diagnostics for the Chinese populations, which is why we have been providing cutting-edge diagnostic solutions and **best/first-in-class vaccines in China for over 30 years.**

...with world-class manufacturing facilities.

Moreover, we bring to China French state of the art manufacturing expertise to deliver high quality healthcare solutions for the benefit of the Chinese population, in China for China:

bioMérieux, the largest French diagnostics company, has three production sites in China including a new site in Suzhou, to deliver **world-class diagnostic solutions for Chinese patients.**

Sanofi, a world leader in vaccines, produces best in class solutions in its Shenzhen plant, to protect Chinese populations against infectious diseases such as influenza. It is the first and only vaccine manufacturing facility owned by a foreign company in China.



Leading partners of the Chinese public health authorities...



We have built long term partnerships with Chinese public health authorities over the last decades, as well as international brands that are successful in China and adapted to individual needs. During the COVID-19 epidemic, our working group members have also closely supported the Chinese public health authorities and China Red Cross Association to provide personal protective equipment and testing devices to epidemic stricken areas in China.

...and key players of the Sino-French partnership.

As part of our long-term commitment to China, our Working Group members have established long term strategic partnerships with the Chinese Government in the context of the Sino-French bilateral partnership.

In 2019, Sanofi signed a Partnership with Shenzhen Municipal government on vaccine innovation, witnessed by President Xi and President Macron.

In 2018, bioMerieux signed an agreement with Huashan Hospital, Fudan University on R&D of Tuberculosis Diagnostics, witnessed by Premier Li Keqiang and then Prime Minister Edouard Philippe.



Innovating to improve public health capabilities.

Here's how we do it:

Build partnerships between public health authorities and world-class prevention & diagnostic leaders, to maximize people's access to innovative vaccines and diagnostic solutions.


Meet us to explore new collaboration opportunities with the French Healthcare Alliance Infectious Diseases Working Group. Leverage our partnerships to introduce more innovative solutions to prevent and diagnose infectious diseases and improve public health capabilities.

Join us to work together to prevent infectious diseases and future outbreaks on local populations and improve epidemic-preparedness and control.

Case Studies

Biomerieux Collaborations with Chinese medical institutions

The “Joint unit” established by bioMérieux and Shanghai Children’s Medical Center, provides robust support to the early diagnosis of infection. The joint unit combines bioMérieux’s clinical diagnostics solutions with SCMC’s R&D capability, which is an exemplary mode of innovation cooperation in Shanghai and will benefit the patients in China.



BioMérieux has signed a new strategic partnership with Shanghai Jiaotong University School of Medicine to establish a joint laboratory of infectious diseases, integrating the expertise, education, R&D capabilities of both sides.

As before, bioMérieux has located the R&D activities to be as close to Chinese patients and clinicians as possible, in order to provide better and more accurate solutions through innovative R&D cooperation.



Agreement with CLSI: CLSI M100 3-YEAR donation to CARSS

More News!

CLSI M100 in China



Through an agreement with CLSI, a program to translate M100 into Chinese was developed by the China Antimicrobial Resistance Surveillance System, which includes 1,500 clinical laboratories as members. Professor Wang Hui, an advisor to the CLSI AST Subcommittee, and Professor Hu Fupin have been leading this effort together with a group of young volunteers who completed the translation in just three months. Forty-six individuals were involved and the project was sponsored by bioMérieux. The Chinese version of M100 in both hard copy and electronic formats is provided free of charge. A comprehensive training program for microbiologists and clinicians has also been developed to explain how to optimally use M100.

Case Studies

Sanofi's commitment to public health in China and to vaccine innovation

Sanofi Pasteur, the vaccines global Business Unit of Sanofi, is striving to protect the health of Chinese people and advance immunization initiatives in China.

Sanofi Pasteur has been continuously introducing innovative vaccines into China, creating many “firsts and bests” such as the first rabies vaccine, the first flu vaccine, and the first pentavalent vaccine ever launched in China. Our 5-in-1 vaccine Pentaxim® has already protected 10 million Chinese children since its launch.

In November 2019, Sanofi Pasteur and the Shenzhen government signed an agreement on Sino-French Strategic Collaboration on Vaccine Innovation witnessed by Chinese President Xi Jinping and French President Emmanuel Macron. Under this partnership, Sanofi Pasteur is sharing its expertise and know-how with the Shenzhen government to jointly explore new ways of improving people's health.

As part of the partnership, the first Greater Bay Area (GBA) Vaccine Summit was held in Shenzhen in September 2020, serving a bridge to facilitate collaborations and academic exchanges between China and global partners, and to jointly explore new options to bolster vaccine innovation for the benefit of the people. The 2nd GBA Vaccine Summit will be held in Shenzhen in October 2021, with the theme of “Innovation, Harmonization, Shared Health”.



Another key initiative is the Greater Bay Area Vaccine International Innovation Center in Shenzhen, the first world-class innovation hub for vaccines in China, with the aim to showcase the value of prevention, incubate innovation and create a global platform for partnerships and exchanges. The Innovation Center will provide an interactive and complete experience for visitors to be inspired by the innovation power of vaccines and is expected to be put into operation in the 2nd half of 2021. improve epidemic-preparedness and control.



E-HEALTH WORKING GROUP



If BYS426 is 12 and BYE3 is not 11, one is probably a member of haplogroup R1b.



Our e-health working group is dedicated to support healthcare providers and pharma companies in their transformation to become Digital Health Leaders, improving their healthcare systems efficiency to benefit both patients and healthcare professionals.

To facilitate this transformation and better address Chinese market needs, our group consisting of the top French players in China, provides insights into the best local e-health practices around the patient & doctor journeys.

We believe that preventative E-Health is the future of Healthcare, bringing a better life for a lower cost.

We understand that E-Health can be complex, which is why we attract only the best French E-Health players that have demonstrated real value proposition along the patient journey for the benefit of patients and healthcare professionals.

How to establish a sustainable partnership with the French healthcare alliance e-health group and their members?

- 1. Read this brochure and meet our members
- 2. Experience their added value and solutions already implemented in China
- 3. Define the solution you need based on your requirements
- 4. We put you in touch with the right companies to establish the right business model and partnership

You are welcome to join our E-Health group. In the meantime, we will map the French E-health players based in China and their value proposition as well as prepare a leaflet presentation to share with you.

Start your Digital Health transformation and increase your market share in E-health and precision medicine that was valued at USD250 Billion in the Post-Covid market by McKinsey in May 2020.

French e-Health presence in China:

10+ French e-health companies, already operating e-Health projects in China across multiple domains.

- Digital hospital, Hospital information system
- Home AI preventative senior care and Chronic Care, patient monitoring, IoT connected devices
- Health data hosting and warehouse
- Patient centric AI platform to assess Chronic Disease and Cancer risks
- Big Data analytics and Data science

Case Studies

Here are a few examples of successful eHealth projects we launched within our eHealth group members that brought significant business opportunities for our members.

■ 1 - DIGITAL HOSPITAL:

- AKILA Care, smart and connected hospital venturing French (ADEN, 3DS, St GOBAIN, Legrand) and Chinese health tech companies.

AKILA Care is a smart and connected turn-key hospital, developed within a single platform and ready to plug into the latest health-tech solutions. Akila Care's modular design shuns traditional construction, allowing delivery of an operational hospital in just 150 days. It links data from buildings, patients and systems for smarter diagnostic solutions, optimized facility operations and a better overall end-user experience. This project is a catalyst of collaboration between ADEN, Dassault System, Saint Gobain, Aegle, Legrand and other major Chinese companies such as Sinopharm, Beijing Chengdong International Modular Housing Corporation.

■ 2 - CONNECTED PATIENT & HEALTH DATA

2.1 Patient Centric AI Preventative platform for Home Senior care and Chronic care.

After 12 years R&D in US, Canada, France and China, HiNounou developed a preventative AI solution platform to help Seniors and Chronic Patients at home to Live Longer Healthier and Happier. It is used in 12 countries. Via a connected home wellness kit, we simulate a patient digital twin profile that combine 5 dimensions of data as well as multiple AI algorithms for early detection and management of Chronic diseases and colon cancer. With the consent of the patient, their Digital Twin profiles are shared with the HCPs at the hospital to improve the follow-up treatment along the patient journey and improve day care once patients have been discharged from hospital.



Case Studies

AI CONNECTED HOME WELLNESS KIT

- DNA Testing**: Identify top 12 chronic diseases predisposition
- Blood pressure Monitor + Oximeter**
- Connected impedance Scale**
- Smart Squeezing Ball**
- ECG**

© HInounou Intelligent Robot Company Ltd. www.hinounou.com

2.2- Shanghai infrastructure hub from Euris China for health data warehousing and hosting.

Euris Health Cloud China: Compliant Cloud platforms for e-health projects.

Cloud infrastructure based in China complying with the country's regulations for healthcare data hosting (China Cyber Security Law & Personal Information Protection Law). The China hub is part of a certified multi-territory Health Cloud network based on best practices (ISO 27001, GDPR, HIPAA, HDS...). It allows companies to easily operate their e-health services in China while respecting their global IT guidelines.

The Health Cloud hub started in China in 2012. It supports foreign and local companies, to operate in compliance their Chinese e-health projects (IPSEN, AIR LIQUIDE, ENGIE, RESVENT...). For a better ecosystem collaboration, an e-Health marketplace is available offering on demand services hosted on the platform, as well as partners' consulting and technologies solutions (ALIBABA, IQVIA, TENCENT...). The Health Cloud platform is now supporting multiple services and e-health projects (RWE, data anonymization, consent management, patient monitoring, clinical trial, telemedicine...)

Health Cloud platform : e-health in China




Certified Healthcare Data Hosting
符合当地法规的全球健康数据托管基础设施

E-Health Marketplace
一个为您相关的健康项目充满即用型的市场服务

Up and running in China since 2012.

- 50+ e-health projects launched
- Reference for local & foreign companies
- 40+ e-health services available on the marketplace




■ 3. INNOVATING FROM CHINA TO THE WORLD

Innovation hubs based in China including top French companies (SANOFI, SERVIER WEHEALTH, 3DS, IPSEN...). Leverage local technologies and bring innovation to Chinese patients and the rest of the world.



1. Sanofi and JD Health strategic partnership in the field of digital healthcare



2. 3D digital twin application to life sciences



French
Healthcare
法国健康产业联盟

WANT TO Follow? Get the latest news & program



WEBSITE



WECHAT GROUP



LINKEDIN

WANT TO GET INVOLVED? Get in touch & being a member

contact@french-healthcare-alliance.com.cn